Detalhe da pesquisa
1.
Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Proteins
; 91(11): 1510-1524, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37449559
2.
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
Br J Cancer
; 129(9): 1389-1396, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37542109
3.
Evidence Regarding Pharmacogenetics in Pain Management and Cancer.
Oncologist
; 28(3): 189-192, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36718020
4.
Relugolix in Clinical Practice: The Best Route for All?
Oncologist
; 28(8): 647-650, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37162497
5.
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Oncologist
; 28(7): 642-e561, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37134294
6.
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
N Engl J Med
; 382(15): 1430-1442, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187457
7.
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.
Blood
; 137(7): 896-907, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976576
8.
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
Oncologist
; 27(3): e273-e285, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274717
9.
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.
Oncologist
; 27(9): 718-e694, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35640474
10.
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Oncologist
; 26(1): e115-e129, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790034
11.
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer.
Oncologist
; 26(9): 729-e1493, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34333820
12.
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Oncologist
; 26(4): 288-e541, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33554406
13.
On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.
Biochem Biophys Res Commun
; 534: 67-72, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33310190
14.
Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
FASEB J
; 34(9): 11395-11404, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32677118
15.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int
; 127(4): 435-444, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969563
16.
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Pediatr Blood Cancer
; 68(11): e29282, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34383370
17.
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Lancet Oncol
; 21(8): 1099-1109, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32645282
18.
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Prostate
; 80(4): 336-344, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31899823
19.
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Cancer
; 126(22): 4936-4947, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32870522
20.
Antibody-drug conjugates for cancer.
Lancet
; 394(10200): 793-804, 2019 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31478503